Keywords: astrazeneca, bayer, stop, co-marketing, baymycard, japan, yakuhin
AstraZeneca and Bayer stop co-marketing Baymycard in Japan
Article | 01 April 2002
Bayer Yakuhin and AstraZeneca have said that their five-yearco-marketing contract in Japan on Baymycard (nisoldipine), a long-acting calcium antagonist, expired ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
